Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ctDNA-FGFR Status as a Predictive Biomarker for FGFR Targeted Therapy

NCT06129084 is registered in ClinicalTrials.gov with Bernie Eigl as lead sponsor.

NCT NCT06129084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06129084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ctDNA-FGFR Status as a Predictive Biomarker for FGFR Targeted Therapy
Lead sponsor
Bernie Eigl
Phase
Observational
Overall status
Active, not recruiting
Start date
January 11, 2021
Completion date
December 31, 2026
Enrollment
260 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic bladder cancer, metastatic urothelial carcinoma